[PDF][PDF] 新型冠状病毒中和抗体研究进展
乔春霞， 王晶， 罗龙龙， 冯健男 - 中国药理学与毒理学杂志, 2021 - cjpt.magtechjournal.com
新型冠状病毒(SARS-CoV-2) 传染性强, 可引起新型冠状病毒肺炎(COVID-19). 抗SARS-CoV-2
抗体安全性高, 特异性强, 中和SARS-CoV-2 的能力显著, 被认为是治疗COVID-19 的理想药物 …
抗体安全性高, 特异性强, 中和SARS-CoV-2 的能力显著, 被认为是治疗COVID-19 的理想药物 …
Human monoclonal antibodies: on the menu of targeted therapeutics against COVID-19
J Chen, R Huang, Y Nie, X Wen, Y Wu - Virologica Sinica, 2020 - Springer
Abstract Coronavirus disease 2019 (COVID-19), reminiscent of the severe acute respiratory
syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world …
syndrome (SARS) outbreak in 2003, has been a tragic disaster to people all over the world …
Analysis of the molecular mechanism of SARS-CoV-2 antibodies
D Jin, J Wei, J Sun - Biochemical and biophysical research communications, 2021 - Elsevier
A newly-emergent beta-coronavirus, SARS-CoV-2, rapidly has become a pandemic since
2020. It is a serious respiratory disease and caused more than 100 million of deaths in the …
2020. It is a serious respiratory disease and caused more than 100 million of deaths in the …
[HTML][HTML] Monoclonal neutralizing antibodies against SARS-COV-2 S protein
LD Cheng, P Li, YC Lin, HX Hu, Y Zhang… - American Journal of …, 2024 - ncbi.nlm.nih.gov
Novel coronavirus pneumonia, also known as coronavirus disease 2019 (COVID-19), is
caused by sub-severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) …
caused by sub-severe acute respiratory syndrome type 2 coronavirus (SARS-CoV-2) …
Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex
M Tada, M Aoyama, A Ishii-Watabe - MAbs, 2023 - Taylor & Francis
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV− 2) causes coronavirus
disease 2019 (COVID− 19). Antibodies induced by SARS-CoV− 2 infection or vaccination …
disease 2019 (COVID− 19). Antibodies induced by SARS-CoV− 2 infection or vaccination …
Screening and characterization of anti-SARS-CoV-2 receptor binding domain antibodies with broad-spectrum neutralizing activity.
NI Wanqi, REN Li, JIN Changzhong… - China Tropical …, 2024 - search.ebscohost.com
Objective To isolate monoclonal B cells specific for the SARS-CoV-2 receptor binding
domain (RBD) from two COVID-19 convalescents, and to screen for broad-spectrum …
domain (RBD) from two COVID-19 convalescents, and to screen for broad-spectrum …
新冠病毒抗体药物研发进展及展望分析
武瑞君， 李治非， 张鑫， 濮润， 敖翼… - 中国生物工程 …, 2020 - manu60.magtech.com.cn
抗体药物以其独特的作用机制和靶向性强, 特异性好等优点, 在恶性肿瘤, 自身免疫性疾病,
感染类疾病的诊断和治疗中发挥着越来越重要的作用, 成为国际创新药物研发的热点 …
感染类疾病的诊断和治疗中发挥着越来越重要的作用, 成为国际创新药物研发的热点 …
抗新型冠状病毒中和抗体药物的研究进展.
那一凡， 金鹏飞， 倪倩， 谭琳… - Evaluation & Analysis …, 2022 - search.ebscohost.com
摘要新型冠状病毒肺炎疫情在全球范围的持续发展促使人们开展针对该疾病的深入研究,
包括治疗药物的研究. 中和抗体药物作为一种很有前景的特异性抗病毒药已成功应用于部分病毒 …
包括治疗药物的研究. 中和抗体药物作为一种很有前景的特异性抗病毒药已成功应用于部分病毒 …
Homologous and heterologous serological response to the N‐terminal domain of SARS‐CoV‐2 in humans and mice
The increasing numbers of infected cases of coronavirus disease 2019 (COVID‐19) caused
by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses serious threats to …
by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) poses serious threats to …
[PDF][PDF] 靶向SARS-CoV-2 受体结合结构域的嵌合抗体表达及功能研究
石慧春， 焦凡珂， 徐巍， 陈永康， 陆路， 邹鹏 - 微生物与感染, 2023 - jmi.fudan.edu.cn
严重急性呼吸综合征冠状病毒2 (severeacuterespiratorysyndromecoronavirus2, SARS-CoV-
2) 感染所致的2019 冠状病毒病(coronavirusdisease2019, COVID-19) 给人民的生命健康造成 …
2) 感染所致的2019 冠状病毒病(coronavirusdisease2019, COVID-19) 给人民的生命健康造成 …